More about

Osimertinib

News
October 13, 2023
1 min watch
Save

VIDEO: Osimertinib plus chemotherapy may benefit some lung cancer subsets

VIDEO: Osimertinib plus chemotherapy may benefit some lung cancer subsets

Osimertinib plus chemotherapy may benefit some lung cancer subsets compared with osimertinib alone, according to recent research from the FLAURA2 trial.

News
September 29, 2023
1 min read
Save

Rybrevant combination extends PFS in EGFR-mutant non-small cell lung cancer

Rybrevant combination extends PFS in <i>EGFR</i>-mutant non-small cell lung cancer

Amivantamab plus lazertinib improved PFS compared with osimertinib as first-line therapy in adults with locally advanced or metastatic EGFR-mutated non-small cell lung cancer, according to the agent’s manufacturer.

News
September 18, 2023
2 min read
Save

Osimertinib plus chemotherapy extends PFS in EGFR-mutated advanced NSCLC

Osimertinib plus chemotherapy extends PFS in <i>EGFR</i>-mutated advanced NSCLC

Osimertinib plus chemotherapy conferred significantly greater improvement in PFS compared with osimertinib alone in patients with EGFR-mutated advanced non-small cell lung cancer, according to study results.

News
September 06, 2023
1 min read
Save

Rybrevant extends PFS in EGFR-mutant lung cancer

Rybrevant extends PFS in <i>EGFR</i>-mutant lung cancer

Amivantamab-vmjw — with or without the addition of lazertinib — improved PFS versus chemotherapy alone in patients with EGFR-mutated non-small cell lung cancer, according to the agent’s manufacturer.

News
August 01, 2023
1 min read
Save

World Lung Cancer Day: Advances in metastatic NSCLC; value of screening for nonsmokers

World Lung Cancer Day: Advances in metastatic NSCLC; value of screening for nonsmokers

Today is World Lung Cancer Day.

News
July 14, 2023
6 min watch
Save

VIDEO: ADAURA results ‘practice affirming’ for lung cancer subset

VIDEO: ADAURA results &lsquo;practice affirming&rsquo; for lung cancer subset

Healio spoke with Howard (Jack) West, MD, associate clinical professor of medical oncology at City of Hope Comprehensive Cancer Center, about results from the ADAURA trial presented at ASCO Annual Meeting.

News
June 22, 2023
3 min watch
Save

VIDEO: ‘We should be offering osimertinib’ for EGFR lung cancer

VIDEO: &lsquo;We should be offering osimertinib&rsquo; for EGFR lung cancer

In this interview, Charu Aggarwal, MD, MPH, discusses results from ADAURA trial presented at this year’s ASCO Annual Meeting.

News
June 17, 2023
2 min read
Save

8 ASCO studies your colleagues are still talking about

8 ASCO studies your colleagues are still talking about

Nearly 7,000 abstracts had been submitted for presentation at this year’s ASCO Annual Meeting.

News
June 15, 2023
1 min watch
Save

VIDEO: ADAURA results ‘practice changing’ for lung cancer

VIDEO: ADAURA results &lsquo;practice changing&rsquo; for lung cancer

CHICAGO — Healio spoke with Karen L. Reckamp, MD, on updated findings from the ADAURA trial presented at ASCO Annual Meeting.

News
June 11, 2023
4 min read
Save

MET status may predict benefit of amivantamab-lazertinib therapy in lung cancer subset

MET status may predict benefit of amivantamab-lazertinib therapy in lung cancer subset

CHICAGO — MET status by immunohistochemistry may predict how patients with osimertinib-treated EGFR-mutated non-small lung cancer will respond to subsequent combination therapy, according to findings presented at ASCO Annual Meeting.

View more